Продолжая использование сайта, вы соглашаетесь с использованием файлов cookie. Подробнее.

GRIPPOL® PLUS FOR CHILDREN

Influenza is an airborne infection accompanied by high fever and a bad general condition. During annual influenza epidemics, up to 30% of children become ill, with young children under 5 years of age accounting for the bulk of cases1.

The morbidity of influenza and ARVI in children is 10 times that of adults².

The influenza virus is constantly mutating, making it difficult to control, forcing the creation of new influenza vaccines every year.

Influenza can entail dangerous consequences

6-12 times

Children 6-12 months. have nearly 6 times higher hospitalization rates compared to 2-4 years old children, and 12 times higher than 5-17 years old children¹

12 times

Prior influenza disease was 12 times times more likely to be detected in children diagnosed with severe pneumonia²

50%

50% of sick children need medical help³

90%

90% sick children are taking medicinal products. Antibiotic prescriptions
increases by 10-30%в³

WHAT IS THE DANGER OF INFLUENZA IN CHILDREN?

Influenza is known to be dangerous for its complications: otitis (inflammation of the middle ear), sinusitis (inflammation of the nasal sinuses) and, of course, pneumonia (lungs inflammation).

Complications after influenza occur in 18-40%³ Influenza pneumonia rapidly develops pulmonary edema followed by heart failure and complications from the kidney and nervous system. In children, the most frequent cause of lethal outcomes in severe influenza is neurotoxemia (impaired consciousness up to coma with circulatory disorder).

INFLUENZA IN CHILDREN WITH CHRONIC CONDITIONS

In children with asthma, chronic lung disease, influenza leads to exacerbations, bouts of breathing difficulties and is complicated by pneumonia. Influenza in children with neurological pathology is accompanied by severe respiratory distress, often with a fatal outcome. In patients with heart disease, it leads to heart failure. The influenza causes an exacerbation of diabetes mellitus, cystic fibrosis and many other already serious diseases.

WHICH CHILDREN NEED VACCINATION?

There are certain categories of children who need the influenza vaccine first:

children who are often ill with colds, with chronic respiratory diseases;
children with chronic diseases of other organs and systems;
children attending school and preschool in contact with peers.

HOW CAN I KEEP MY CHILD SAFE FROM THE INFLUENZA?

Vaccination is a no-regret way of protecting children from the severe effects of influenza at 6 months of age and above, and is a priority in the health care system in Europe and the USA.

Vaccination is the most effective method to prevent influenza

Reduces flu incidence by 90%⁶
Reduces pediatric flu hospitalizations by 75%⁷
Reduces the morbidity of acute otitis media in children by 36%⁸
Reduces the frequency of all ARVIs by 56%⁶

WHO and Ministry of Health of RF recommend mandatory influenza vaccination⁹

Children from 6 months of age
1-11 year school pupils
Pregnant women

Grippol® Plus has high epidemiological efficacy in vaccinating schoolchildren

High vaccination coverage ensures a 4.7-fold reduction in influenza and ARVI morbidity by more than 40%
Creating collective immunity helps to reduce the morbidity among the unvaccinated

The protective effect after influenza vaccination occurs on average 2 weeks after the procedure and lasts for a year¹¹.

HOW SAFE IS THE GRIPPOL PLUS VACCINE IN CHILDREN?

Additional safety of Grippol^® plus vaccination is provided to:

No preservatives^* or antibiotics, reducing the risk of hypersensitivity reactions in the vaccine composition.
Individual syringe dose with special atraumatic needle for painless vaccination
High-tech manufacturing conditions according to GWP standards

Extensive experience with Grippol^® Plus confirms the efficacy and safety of the vaccine

More than 13 million children have been vaccinated with Grippol^® Plus every year since 2009, as part of the National Preventive Vaccination Calendar
Opportunity for joint infusion with vaccines of the National Preventive Vaccination Calendar

^*For the influenza immunization of children attending pre-schools, students in grades 1-11 and pregnant women, the use of preservative-free vaccines⁹

Symptoms	Children 6 months - 2 years (n=70) after 2nd vaccination	Дети 3-17 лет (n=100)
Local reactions
Soreness at the injection site	-	13.1%
Hyperemia at the injection site	1.4%	5.9%
Induration at the injection site	1.4%	5.9%
General reactions
Temperature, 37-38 °C	-	0.7%
Headache	-	3.3%

Grippol^® Plus has low reactogenicity and high safety profile
93.5% of those vaccinated had no overall reaction to the Grippol^® plus vaccine¹²
All local reactions refer to normal mild post-vaccination reactions¹²

ARE THERE ANY CONTRAINDICATIONS TO VACCINATION?

The only conditions that must be taken into account when planning vaccinations are

lack of acute infectious disease

Vaccination also contraindicated:

If your child is highly allergic to chicken egg proteins, as chicken embryos are used in the production of influenza vaccines and traces of these proteins may be present in the vaccine;
If your child is highly allergic to chicken egg proteins, as chicken embryos are used in the production of influenza vaccines and traces of these proteins may be present in the vaccine;
complications following previous vaccinations;
exacerbation of existing chronic diseases;
other conditions accompanied by a fever.

To identify these limitations, the child is required to be examined by a pediatrician before being vaccinated. He also determines indications for vaccination.

Administration scheme

Children aged 6 months to 35 months inclusive - 0.25 ml twice with an interval of 3-4 weeks - in the anterolateral surface of the thigh
Children over 36 months old and adults -0.5ml - single injection in the deltoid muscle

1. Committee on Infection Diseases. Pediatrics 2008; 121(4): e1017; 2. Marinich I.G. Social aspects of the epidemic process in influenza and other acute respiratory diseases in Russia. Research report, 2009; 3. Tatochenko V.K. et al. immunoprophlaxis-2009. Handbook. M–2009 4. www.who.int/wer No. 33, 2005; 5. Munoz F. Influenza virus infection in infancy and early childhood. Ped Resp Rev, 2003; 4: 99-104; 6. Semenov B.F. RMJ, vol. 11, No. 22, 2003; 7. Spaude K.A. et al. Influenza vaccination… Arch intern med. 2007; 167, 53; 8. Ozgur S.K. et al. Effectiveness of inactivated influenza vaccine… Pediatr. Infect. Dis. J. 2006; 25 (5): 401-404; 9. Order N.125n of the Ministry of Health of RF dated March 21, 2014 “On Approval of the National Preventive Vaccination Calendar and the Calendar of Preventive Immunizations for Epidemic Indications”; 10. Il’ina T.N. Evaluation of the anti-epidemic efficacy of influenza inactivated polymer-subunit vaccine in schoolchildren. Contemporary Pediatrics Issues, No. 5, 2009; 11. Package leaflet for Grippol Plus; 12. Harith S.M. et al. Safety and efficacy of Grippol® plus when administered separately and in combination with vaccines from the National Vaccine Calendar. Contemporary Pediatrics Issues, No. 1; vol.13/ 2014; 13. Konovalov I.V., Shamsheva O.V. First results of the safety and immunological efficacy assessment of the combined use of National Preventive Vaccination Calendar vaccines in children aged 6-7 years. Contemporary Pediatrics Issues, vol 11, No. 4, 2012.